210024.full.pdf (94.03 kB)
Download file

Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment.

Download (94.03 kB)
journal contribution
posted on 01.09.2021, 08:42 by Anna C Murphy, Claire Boddy, Peter Bradding
Inhaled corticosteroids (ICS) are the core component of asthma treatment and the only maintenance therapy known to prevent asthma death. There is currently no evidence that biologics prevent asthma death in people with asthma, and as such, biologics cannot be recommended as an alternative to ICS therapy. Taking the time to assess adherence and provide interventions and education to support patients in asthma self-management has been shown to improve patient outcomes. It is therefore our responsibility as healthcare professionals to ensure that patients are supported, educated and motivated to adhere to ICS therapy before progressing to biologic therapies.

History

Citation

Breathe 2021;17: 210024.

Author affiliation

Department of Respiratory Sciences, University of Leicester

Version

VoR (Version of Record)

Published in

Breathe

Volume

17

Issue

2

Pagination

210024

Publisher

European Respiratory Society (ERS)

issn

1810-6838

eissn

2073-4735

Acceptance date

07/05/2021

Copyright date

2021

Available date

01/09/2021

Spatial coverage

England

Language

eng

Usage metrics

Categories

Keywords

Exports